WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that key data from across its dermatology portfolio, including multiple late-breaking abstracts, will be presented at the ...

18-month duration of response (DOR) data from ENVISION, and integrated patient-reported outcomes (PROs) from UGN-102-treated patients in OPTIMA II, ATLAS and ENVISION in low-grade intermediate-risk ...

Data storytelling has become a powerful part of the communications toolkit, allowing both journalists and marketers to communicate key messages by using data and data visualization to drive articles, ...

– Late-Breaking Data from the Phase 3 ASCENT-04/KEYNOTE-D19 Study Evaluating Trodelvy ® plus Keytruda ® in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer – FOSTER CITY, Calif. & SANTA ...